NCT04870281终止不适用
BIO-AffectDX Clinical Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 13
- 试验地点
- 23
- 主要终点
- Change in Clinical Composite Score from baseline
研究概览
简要总结
The purpose of the BIO-AffectDX Study is to prospectively evaluate improvement from baseline in heart failure subjects with atrial fibrillation (AF) implanted with a two-lead CRT-DX system, with emphasis on a comparison of patient outcomes between AF subtypes.
详细描述
There is a need for more evidence about the benefits of Cardiac Resynchronization Therapy (CRT) in a patient population with heart failure and atrial fibrillation. The BIO-AffectDX Study will gather information about adults with heart failure and atrial fibrillation who are treated with a CRT-DX device from many locations across the United States. The BIO-AffectDX Study will look at the results of treatment in participants with the primary goal to evaluate the improvement in overall health prior to device implant through 12 months. Overall health will be measured by your study doctor for AF improvement, physical fitness, and general quality of life.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Standard CRT-D indication according to current guidelines
- •Patient has documented history of paroxysmal, persistent, or long-standing persistent atrial fibrillation
- •De novo implant or upgrade from a DX implantable cardioverter-defibrillator (ICD) system
- •Implant planned to occur within 30 days of consent
- •Patient is able to understand English or Spanish
- •Patient is able to understand the nature of the study and provide informed consent
- •Patient is willing and able to complete all routine study visits at the investigational site for up to 12 months of follow-up
- •Patient is willing to utilize BIOTRONIK Home Monitoring® via CardioMessenger
- •Patient age is greater than or equal to 18 years
- •After consent has been signed, additional inclusion criteria must be fulfilled for study participation:
- •Baseline subject assessment is evaluated as New York Heart Association class II, III or ambulatory IV heart failure at study Enrollment Visit
- •Baseline subject assessment of six-minute walk test is completed at study Enrollment Visit and walk distance ≤ 450 meters (1,476 feet)
排除标准
- •Contraindication to CRT-D/CRT-DX
- •Patient has current or previous atrial pacing need
- •Patient is considered for a His Bundle Pacing system
- •Patient has current or previous pacemaker, non-DX ICD implant, or bi-ventricular pacing system prior to enrolling
- •Patient is currently planned for a pulmonary vein isolation catheter ablation procedure within 3 months of consent
- •Patient life expectancy is less than 1 year
- •Patient is expected to receive heart transplantation or ventricular assist device within 1 year after implant
- •Patient is expected to have a cardiac surgical procedure, such as coronary artery bypass graft or valve transcatheter replacement/repair or surgery, planned to occur within 6-months after implant (excludes atrioventricular node ablation procedures)
- •Patient is currently on dialysis, or is expected to receive dialysis within 1 year of implant
- •Patient is enrolled in any investigational cardiac device or drug trial that might significantly affect the studied outcomes
- •Any condition (e.g. severe arthritis, wheelchair bound, etc.) preventing the patient from performing the required six-minute walk test
- •Conditions that prohibit placement of any of the system leads
- •Patient reports pregnancy at the time of consent
结局指标
主要结局
Change in Clinical Composite Score from baseline
时间窗: 12 months
次要结局
- Change in six-minute walk distance from baseline for all patients and by atrial fibrillation sub-type(6 and 12 months)
- Change in atrial fibrillation burden from baseline for all patients and by atrial fibrillation sub-type(6 and 12 months)
- Change in quality of life questionnaires from baseline for all patients and by atrial fibrillation sub-type(6 and 12 months)
- Rate of conversion to sinus rhythm(12 months)
- Rate of composite all-cause death and heart failure(12 months)
- Change in New York Heart Association class from baseline for all patients and by atrial fibrillation sub-type(6 and 12 months)
- Change in Clinical Composite Score from baseline(6 months)
- Rate of major complications(12 months)
研究者
研究点 (23)
Loading locations...
相似试验
Unknown
不适用
Prognostic Biomarker for CRCColorectal CancerNCT03928652Sixth Affiliated Hospital, Sun Yat-sen University1,050
已完成
不适用
ADvance II Study: DBS-f in Patients With Mild Alzheimer's DiseaseAlzheimer DiseaseNCT03622905Functional Neuromodulation Ltd74
已完成
1 期
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue SarcomaSoft Tissue SarcomaNCT02783599Eli Lilly and Company51
Unknown
不适用
Impact of Burnout on Cardiovascular and Immune Biomarkers in Healthcare Professionals - Covid-19 Pandemic in Abu DhabiCardiovascular Risk FactorBurnoutImmune DeficiencyNCT04422418Khalifa University for Science and Technology200
已完成
不适用
12-Month Extension Study of Dialectical Behavior Therapy for Youth With Bipolar DisorderBipolar DisorderNCT04283188Sunnybrook Health Sciences Centre15